Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, octubre 23
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
CryoPort Inc
CYRX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$17.70
-0.13
-0.76%
Últ. Act.: Oct 23, 12:28 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Ganancias:
Beneficios de Q3 2026 dentro de 13 días de ahora en jue nov 5th, después del cierre del mercado
CryoPort Financials
CryoPort (CYRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Conference Call: CryoPort Affirms FY2026 Sales Guidance of $192.000M-$196.000M vs $194.390M Est
CryoPort (NASDAQ:CYRX) affirms FY2026 sales outlook from $192.000 million-$196.000 million to $192.000 million-$196.000 million vs $194.390 million estimate.
Benzinga Newsdesk
PRO
CryoPort Q2 Adj. EPS $(0.20) Misses $(0.19) Estimate, Sales $48.971M Beat $48.207M Estimate
CryoPort (NASDAQ:CYRX) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.19) by 5.26 percent. This is a 16.67 percent increase over losses of $(0.24) per share from the
Benzinga Newsdesk
Cryoport Posts Revenue Beat In Q1 As Clinical Trial Support Hits All-Time High — 'A Strong Start To 2026'
Cryoport released financial results for Q1 of fiscal 2026 Monday after the closing bell.
Henry Khederian
PRO
CryoPort Raises FY2026 Sales Guidance from $190.000M-$194.000M to $192.000M-$196.000M vs $191.834M Est
CryoPort (NASDAQ:CYRX) raises FY2026 sales outlook from $190.000 million-$194.000 million to $192.000 million-$196.000 million vs $191.834 million estimate.
Benzinga Newsdesk
PRO
CryoPort Q1 Adj. EPS $(0.25) Misses $(0.22) Estimate, Sales $47.800M Beat $44.862M Estimate
CryoPort (NASDAQ:CYRX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 10.71 percent increase over losses of $(0.28) per share from the
Benzinga Newsdesk
Earnings Scheduled For May 4, 2026
Benzinga Insights
